Cyprotex PLC (AIM:CRX), the preclinical ADME-Tox services company, today announces the launch of its new Genomic ADME service, making Cyprotex the pioneering discovery-focused ADME Tox contract research organisation providing drug researchers with actionable data about genomic differences in drug response at the early stages of drug development.
The new service, named gADME™, enables drug developers to identify which enzymes play a role in the metabolism of their drugs, to understand the impact of genetic polymorphisms on that metabolism, and to devise dose adjustment strategies. This gives drug developers the opportunity to substantially improve patient care through identifying and compensating for variability in patient drug response, and enabling personalised dose regimens.
Cyprotex’s gADME™ service combines genomics with ADME to predict inter-individual variability in human pharmacokinetics. The technology utilises a panel of proprietary enzyme systems providing a comprehensive range of drug metabolising enzymes, including genetic variants of these enzymes.
To find out more about what gADME™ can do, click here.
Genetic polymorphisms (variants) in drug metabolism greatly affect plasma levels in vivo, making them one of the major causes of both adverse drug reactions and of lack of drug efficacy in humans. The most commonly reported genetic polymorphisms in drug metabolism are those for the cytochrome P450 enzymes (CYPs), a diverse and key group of enzymes. Expression of these enzymes and the number of active and inactive alleles differ significantly as a function of ethnicity, resulting in sometimes large variations in drug plasma levels between individuals of different ethnic origins.
Until now, such variances in drug plasma levels has meant that drug developers have to discard potential drugs whose metabolism is substantially dependent on these polymorphic enzymes and drugs that could have benefited one or more ethnic groups are not being pursued because of adverse effects or lack of efficacy within other ethnic groups.
Dr. Katya Tsaioun, Cyprotex’s Chief Scientific Officer, comments on the launch of gADME™: “Many potentially valuable drugs are being discarded in early development because they are metabolised by polymorphic CYPs, which puts the drugs at risk of excessively variable drug plasma levels among patients. Cyprotex’s gADME™ service allows drug developers to understand the effect of genetic polymorphisms on drug toxicity and efficacy. This understanding will enable drug developers to identify appropriate dose adjustment strategies personalised for an individual’s genotype. This in turn can enable existing therapies to be repositioned, and successful development of drugs that would have heretofore been discarded.”
Dr Anthony Baxter, Cyprotex’s Chief Executive Officer, comments: “The launch of gADME™ represents a significant milestone in Cyprotex’s scientific evolution. In the past year Cyprotex diversified into proprietary services spearheaded by our predictive toxicology technology CellCiphr™ and now gADME™ for genetic ADME. Last year Cyprotex entered the in vitro toxicology market and we can now offer a large portfolio of predictive toxicology services.”
For further information:
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel